ARDX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Ardelyx (ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026

If you purchased or acquired securities in Ardelyx between January 13, 2025 and August 6, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP , a leading national securities law firm, is investigating potential claims against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX) and reminds investors of the November 16, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that the true state of Ardelyx's commercial performance and growth prospects for XPHOZAH and IBSRELA, and in particular the increasing payer-related access and reimbursement barriers affecting patient access, more stringent prior authorization requirements and step edit requirements that slowed new-patient starts and delayed prescription fulfillment. On August 6, 2026, Ardelyx issued a press release a reduction in its full-year 2026 IBSRELA revenue guidance and withdrawal of its long-term XPHOZAH revenue guidance. Management attributed the reduction on significantly increased payer utilization-management processes that restricted patient access to IBSRELA and slowed new-patient starts. Further, Defendants withdrew their long-term XPHOZAH revenue guidance due to "evolving market dynamics" and uncertainty regarding future growth projections. On this news, the price of Ardelyx's common stock declined dramatically. From a closing market price of $4.87 per share on August 6, 2026, Ardelyx's stock price fell to $4.00 per share on August 7, 2026, a decline of about 18% in the span of just a single day.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

The lawsuit alleges Ardelyx misled investors about the commercial performance of XPHOZAH and IBSRELA and failed to adequately disclose increasing payer-related access and reimbursement barriers affecting growth.